The markets opened mixed with the Dow adding 11 points to 17,646 while Nasdaq slipped 5 points to 4,682 as Japan’s economy unexpectedly retreated back into a recession.
On the upside
Celldex Therapeutics (Nasdaq: CLDX) reported positive interim data from a Phase 2 study of rindopepimut in treating patients with EGFRvIII-positive glioblastoma.
Baker Hughes (NYSE: BHI) will be acquired by Halliburton (NYSE: HAL) in a cash and stock deal valued at approximately $34.6 billion.
Amicus Therapeutics (Nasdaq: FOLD) reported positive Phase 3 data from its Fabry disease treatment migalastat.
On the downside
The Wall Street Journal reported that merger discussions between Hasbro (Nasdaq: HAS) and DreamWorks (Nasdaq: DWA) have faltered.
Denbury Resources (NYSE: DNR) will slash its capital spending in 2015 by 50% to $550 million and announced the resignation of chief operating officer Craig McPherson.
Inovio Pharmaceuticals (Nasdaq: INO) and Roche ended their collaboration to jointly develop Inovio’s prostate cancer immunotherapy INO-5150.
In the broad market, declining issues outpaced advancers by a margin of 10 to 9 on the NYSE and by a margin of more than 10 to 9 on Nasdaq. The broader S&P 500 slipped 2 points to 2037. Bitcoin gained $11 to $398.
